Read the source
with the explanation.

Sources and context

Checked October 5, 2026. Study summaries identify their evidence limits. Provider pages describe advertised offers, not independently measured care performance.

1. MedlinePlus — GLP-1 agonistsPatient education; mechanism context
2. Wilding et al. — STEP 1 extension (PubMed abstract)Exploratory follow-up study; abstract-level summary
3. FDA — labeling for prescription medicines, questions and answersRegulatory labeling guidance
4. FDA — managing the benefits and risks of medicinesFederal patient education
5. Noom Med — current program pricingProvider offer; branded pathway only in this review
6. Noom — branded-medication prescriptions and pharmacyProvider workflow terms
7. CoreAge Rx — official treatment pagesProvider offer
8. CoreAge Rx — tirzepatide offerProvider offer
9. CoreAge Rx Help Center — Pricing & PlansProvider billing terms
10. SuperHealthy Rx — current GLP-1 offerProvider offer
11. Likeness Rx — GLP-1 plans and billingProvider offer
12. Ro Body — membership and medication costsProvider offer
13. WeightWatchers — Med+ membership and medicationProvider offer
14. LillyDirect — pharmacy access and independent care optionsManufacturer access program
15. FDA — concerns with unapproved GLP-1 drugsRegulator guidance
16. FDA — compounding questions and answersRegulator guidance
17. FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
18. NIDDK — prescription medications for overweight and obesityFederal patient education